High Dose Vitamin D Supplementation Does Not Affect Biochemical Bone Markers in Multiple Sclerosis - a Randomized Controlled Trial

Overview

Journal BMC Neurol

Publisher Biomed Central

Specialty Neurology

Date 2017 Apr 6

PMID 28376767

Citations 8

Authors

Trygve Holmoy

Jonas Christoffer Lindstrom

Erik Fink Eriksen

Linn Hofsoy Steffensen

Margitta T Kampman

Affiliations

Soon will be listed here.

Abstract

Background: People with multiple sclerosis have high risk of osteoporosis and fractures. A poor vitamin D status is a risk factor for MS, and vitamin D supplementation has been recommended both to prevent MS progression and to maintain bone health.

Methods: We assessed the effect of 20,000 IU vitamin D weekly compared to placebo on biochemical markers of bone metabolism in 68 persons with relapsing remitting multiple sclerosis.

Results: Serum levels of 25-hydroxyvitamin D more than doubled in the vitamin D group, and parathyroid hormone decreased in the vitamin D group compared to the placebo group at week 48 and week 96. There was however no effect on bone formation as measured by procollagen type I N propeptide (PINP), or on bone resorption as measured by C-terminal cross-linking telopeptide of type I collagen (CTX1). Neither PINP nor CTX1 predicted bone loss from baseline to week 96.

Conclusions: These findings corroborate the previously reported lack of effect of weekly high dose vitamin D supplementation on bone mass density in the same patients, and suggest that such vitamin D supplementation does not prevent bone loss in persons with MS who are not vitamin D deficient.

Trial Registration: The trial was registered at ClinicalTrials.gov on April 4 2008, registration number NCT00785473 .

Citing Articles

Nutritional interventional studies in patients with multiple sclerosis: a scoping review of the current clinical evidence.

Tryfonos C, Chrysafi M, Vadikolias K, Berberoglou L, Vorvolakos T, Dimoliani S J Neurol. 2024; 271(4):1536-1570.

PMID: 38177875 DOI: 10.1007/s00415-023-12140-z.

The Impact of Vitamin D Low Doses on Its Serum Level and Cytokine Profile in Multiple Sclerosis Patients.

Walawska-Hrycek A, Galus W, Hrycek E, Kaczmarczyk A, Krzystanek E J Clin Med. 2021; 10(13).

PMID: 34202863 PMC: 8269072. DOI: 10.3390/jcm10132781.

Vitamin D Megadose: Definition, Efficacy in Bone Metabolism, Risk of Falls and Fractures.

Narvaez J, Maldonado G, Guerrero R, Messina O, Rios C Open Access Rheumatol. 2020; 12:105-115.

PMID: 32607018 PMC: 7295536. DOI: 10.2147/OARRR.S252245.

Multiple Sclerosis Patients Show Lower Bioavailable 25(OH)D and 1,25(OH)D, but No Difference in Ratio of 25(OH)D/24,25(OH)D and FGF23 Concentrations.

Vlot M, Boekel L, Kragt J, Killestein J, van Amerongen B, de Jonge R Nutrients. 2019; 11(11).

PMID: 31731605 PMC: 6893545. DOI: 10.3390/nu11112774.

An Update on Vitamin D and Disease Activity in Multiple Sclerosis.

Smolders J, Torkildsen O, Camu W, Holmoy T CNS Drugs. 2019; 33(12):1187-1199.

PMID: 31686407 PMC: 6890630. DOI: 10.1007/s40263-019-00674-8.

References

Steffensen L, Mellgren S, Kampman M . Predictors and prevalence of low bone mineral density in fully ambulatory persons with multiple sclerosis. J Neurol. 2009; 257(3):410-8. DOI: 10.1007/s00415-009-5337-6. View

Hjartaker A, Andersen L, Lund E . Comparison of diet measures from a food-frequency questionnaire with measures from repeated 24-hour dietary recalls. The Norwegian Women and Cancer Study. Public Health Nutr. 2007; 10(10):1094-103. DOI: 10.1017/S1368980007702872. View

Benth J, Myhr K, Loken-Amsrud K, Beiske A, Bjerve K, Hovdal H . Modelling and prediction of 25-hydroxyvitamin D levels in Norwegian relapsing-remitting multiple sclerosis patients. Neuroepidemiology. 2012; 39(2):84-93. DOI: 10.1159/000339360. View

Huang Z, Qi Y, Du S, Chen G, Yan W . BMI levels with MS Bone mineral density levels in adults with multiple sclerosis: a meta-analysis. Int J Neurosci. 2014; 125(12):904-12. DOI: 10.3109/00207454.2014.988332. View

Rosjo E, Lossius A, Abdelmagid N, Lindstrom J, Kampman M, Jorgensen L . Effect of high-dose vitamin D supplementation on antibody responses against Epstein-Barr virus in relapsing-remitting multiple sclerosis. Mult Scler. 2016; 23(3):395-402. DOI: 10.1177/1352458516654310. View

Dobson R, Ramagopalan S, Giovannoni G . Bone health and multiple sclerosis. Mult Scler. 2012; 18(11):1522-8. DOI: 10.1177/1352458512453362. View

Bhargava P, Steele S, Waubant E, Revirajan N, Marcus J, Dembele M . Multiple sclerosis patients have a diminished serologic response to vitamin D supplementation compared to healthy controls. Mult Scler. 2015; 22(6):753-60. PMC: 4758937. DOI: 10.1177/1352458515600248. View

Hearn A, Silber E . Osteoporosis in multiple sclerosis. Mult Scler. 2010; 16(9):1031-43. DOI: 10.1177/1352458510368985. View

Gupta S, Ahsan I, Mahfooz N, Abdelhamid N, Ramanathan M, Weinstock-Guttman B . Osteoporosis and multiple sclerosis: risk factors, pathophysiology, and therapeutic interventions. CNS Drugs. 2014; 28(8):731-42. DOI: 10.1007/s40263-014-0173-3. View

10.

Silk L, Greene D, Baker M, Jander C . The effect of calcium and vitamin D supplementation on bone health of male Jockeys. J Sci Med Sport. 2016; 20(3):225-229. DOI: 10.1016/j.jsams.2016.08.004. View

11.

Kampman M, Steffensen L . Comment on Shuhaibar et al.: Favourable effect of immunomodulator therapy on bone mineral density in multiple sclerosis. Ir J Med Sci. 2009; 178(2):235-6. DOI: 10.1007/s11845-009-0275-y. View

12.

Kampman M, Eriksen E, Holmoy T . Multiple sclerosis, a cause of secondary osteoporosis? What is the evidence and what are the clinical implications?. Acta Neurol Scand Suppl. 2011; (191):44-9. DOI: 10.1111/j.1600-0404.2011.01543.x. View

13.

Priemel M, von Domarus C, Klatte T, Kessler S, Schlie J, Meier S . Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res. 2009; 25(2):305-12. DOI: 10.1359/jbmr.090728. View

14.

Pludowski P, Holick M, Grant W, Konstantynowicz J, Mascarenhas M, Haq A . Vitamin D supplementation guidelines. J Steroid Biochem Mol Biol. 2017; 175:125-135. DOI: 10.1016/j.jsbmb.2017.01.021. View

15.

Steffensen L, Jorgensen L, Straume B, Mellgren S, Kampman M . Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. J Neurol. 2011; 258(9):1624-31. PMC: 3165120. DOI: 10.1007/s00415-011-5980-6. View

16.

Loken-Amsrud K, Holmoy T, Bakke S, Beiske A, Bjerve K, Bjornara B . Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment. Neurology. 2012; 79(3):267-73. DOI: 10.1212/WNL.0b013e31825fdf01. View

17.

Jorde R, Grimnes G, Hutchinson M, Kjaergaard M, Kamycheva E, Svartberg J . Supplementation with vitamin D does not increase serum testosterone levels in healthy males. Horm Metab Res. 2013; 45(9):675-81. DOI: 10.1055/s-0033-1345139. View

18.

Munger K, Levin L, Hollis B, Howard N, Ascherio A . Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006; 296(23):2832-8. DOI: 10.1001/jama.296.23.2832. View

19.

Johansson H, Oden A, Kanis J, McCloskey E, Morris H, Cooper C . A meta-analysis of reference markers of bone turnover for prediction of fracture. Calcif Tissue Int. 2014; 94(5):560-7. DOI: 10.1007/s00223-014-9842-y. View

20.

Bazelier M, van Staa T, Uitdehaag B, Cooper C, Leufkens H, Vestergaard P . Risk of fractures in patients with multiple sclerosis: a population-based cohort study. Neurology. 2012; 78(24):1967-73. PMC: 3369507. DOI: 10.1212/WNL.0b013e318259e0ff. View